STOCK MARKET BSE NSE

COVID-19 vaccine human trial: Vital signs of volunteers normal, says doctor

In all, 25 candidates will be given the vaccine in the next seven days.

Published: 27th August 2020 01:55 PM  |   Last Updated: 27th August 2020 01:56 PM   |  A+A-

COVID Vaccine

For representational purposes (Photo | AP)

By PTI

PUNE: Vital health parameters of the two volunteers, who have been administered the Oxford COVID-19 vaccine candidate at a medical college here as part of phase II clinical trial, are normal, a senior official from the medical facility said on Thursday.

Two men, aged 32 and 48, were given the first shot of the 'Covishield' vaccine, being manufactured by Pune-based Serum Institute of India (SII), at Bharti Vidyapeeth's Medical College and Hospital on Wednesday.

The dose will be repeated after one month, an official said.

"Since yesterday, our medical team is in touch with the two volunteers and both are fine.

They do not have any pain, fever, injection-side reaction or systemic illness post-vaccination," the medical college and hospital's deputy medical director Dr Jitendra Oswal said.

After the vaccine was administered on Wednesday, both the volunteers were observed for 30 minutes and later allowed to go home, he said.

FOLLOW COVID-19 LIVE UPDATES HERE

"They have been given all the necessary emergency numbers (to contact in case of need) and our medical team is also conducting follow-ups with them," he added.

The vaccine dose will be repeated on both the volunteers after one month, the hospital's medical director Dr Sanjay Lalwani said on Wednesday.

He said in all, 25 candidates will be given the vaccine in the next seven days.

Dr Sonali Palkar, in-charge of the medical college's research cell, said four to five persons were screened on Wednesday and a decision to administer the vaccine to them as part of the clinical trial is subject to their COVID-19 and antibody test reports.

SII, the world's largest vaccine maker has signed an agreement to manufacture the potential vaccine developed by the Jenner Institute of Oxford University in collaboration with British-Swedish pharma company AstraZeneca.

More from Nation.

Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

IPL_2020
flipboard facebook twitter whatsapp